NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company is headquartered in Zurich, Zuerich and currently employs 1 full-time employees. The company went IPO on 2021-01-29. The firm focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The firm serves customers worldwide.
Follow-Up Questions
Who is the CEO of NLS Pharmaceutics AG?
Mr. Alexander Zwyer is the Chief Executive Officer of NLS Pharmaceutics AG, joining the firm since 2015.
What is the price performance of NLSP stock?
The current price of NLSP is $2.1, it has increased 1.94% in the last trading day.
What are the primary business themes or industries for NLS Pharmaceutics AG?
NLS Pharmaceutics AG belongs to Pharmaceuticals industry and the sector is Health Care
What is NLS Pharmaceutics AG market cap?
NLS Pharmaceutics AG's current market cap is $10.3M
Is NLS Pharmaceutics AG a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for NLS Pharmaceutics AG, including 0 strong buy, 0 buy, 3 hold, 1 sell, and 0 strong sell
